ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.045

-3.1%

1:53 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

CCS648

mannamal

To: mannamal who wrote (969)	4/23/2025 2:29:17 PM
From: Huggenberg	2 Recommendations Read Replies (1) of 1229

The question now is: Will the combination of Tislelizumab (anti-PD-1) and Anktiva surpass the effectiveness of Ivonescimab (bispecific anti-PD-1 and VEGF)? Additionally, what are the treatment costs of the two drugs compared to the monodrug?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next